温肾健脾汤联合美沙拉嗪治疗溃疡性结肠炎临床研究
DOI:
CSTR:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R574.62

基金项目:


Clinical Study on Wenshen Jianpi Tang Combined with Mesalazine for Ulcerative Colitis
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察自拟温肾健脾汤联合美沙拉嗪治疗溃疡性结肠炎(UC) 的临床疗效及其对肠黏膜镜像积分、复发率及炎症因子的影响。方法:选取86 例UC 患者,按随机数字表法分为治疗组和对照组各43 例。对照组采用美沙拉嗪治疗,治疗组在对照组的基础上加用温肾健脾汤治疗。比较2 组治疗前后中医证候和肠黏膜镜像积分、炎症因子[肿瘤坏死因子-α(TNF-α)、白细胞介素-17(IL-17) 和白细胞介素-23(IL-23)]水平的变化,统计其临床疗效、不良发应发生率、复发率情况。结果:治疗组总有效率为95.35%,对照组为79.07%,2 组比较,差异有统计学意义(P<0.05)。治疗前,2 组中医证候、肠黏膜镜像积分比较,差异无统计学意义(P>0.05);治疗后,2 组治疗组中医证候、肠黏膜镜像积分均较治疗前降低(P<0.05),且治疗组2 项积分均低于对照组(P<0.05)。治疗前,2 组血清TNF-α、IL-17、IL-23 水平比较,差异无统计学意义(P>0.05);治疗后,2 组血清TNF-α、IL-17、IL-23 水平均较治疗前降低(P<0.05),且治疗组各项指标均低于对照组(P<0.05)。随访6 个月,治疗组复发率为2.44%,对照组为23.53%,2 组比较,差异有统计学意义(P<0.05)。治疗组不良反应发生率为4.65%,对照组为23.26%,2 组比较,差异有统计学意义(P<0.05)。结论:温肾健脾汤联合美沙拉嗪治疗UC 临床疗效显著,能有效改善患者中医证候和肠黏膜镜像积分,缓解机体炎症反应,降低复发率和不良反应发生率。

    Abstract:

    Abstract: Objective: To observe the clinical effect of the therapy of self- made Wenshen Jianpi tang combined with mesalazine on ulcerative colitis(UC) and its effect on the score of mirror image of intestinal mucosal, recurrence rate and inflammatory factors. Methods:A total of 86 patients with UC were selected and divided into the treatment group and the control group according to the random number table method, with 43 cases in each group. The control group was treated with mesalazine,and the treatment group was additionally treated with Wenshen Jianpi tang based on the treatment of the control group. Before and after treatment, the changes of scores of Chinese medicine syndrome and mirror image of intestinal mucosa and levels of inflammatory factors,including tumor necrosis factor-α(TNF-α),interleukin-17(IL-17) and interleukin-23(IL-23),were compared between the two groups,and the clinical effects,incidence of adverse reactions and recurrence rates were counted. Results: The total effective rate was 95.35% in the treatment group, higher than that of 79.07% in the control group,the difference being significant(P<0.05). Before treatment,there was no significant difference in the comparison of scores of Chinese medicine syndrome and mirror image of intestinal mucosa between the two groups(P> 0.05);after treatment,the scores of Chinese medicine syndrome and mirror image of intestinal mucosa in the two groups were decreased when compared with those before treatment(P<0.05), and the two scores in the treatment group were lower than those in the control group(P<0.05). Before treatment,there was no significant difference in the comparison of levels of serum TNF- α,IL-17 and IL-23 between the two groups(P>0.05);after treatment,the above levels in the two groups were decreased when compared with those before treatment(P<0.05),and the levels of inflammatory indexes in the treatment group were lower than those in the control group(P<0.05). The recurrence rate was 2.44% in the treatment group and 23.53% in the control group after 6 months follow- up, the difference being statistically significant(P<0.05). After treatment, the incidence of adverse reactions was 4.65% in the treatment group and 23.26% in the control group, the difference being significant(P<0.05). Conclusion: The therapy of Wenshen Jianpi tang combined with mesalazine has a significant clinical effect on UC,which can effectively improve the scores of Chinese medicine syndrome and mirror image of intestinal mucosal,alleviate the inflammatory responses of the body,and reduce the recurrence rate and the incidence of adverse reactions.

    参考文献
    相似文献
    引证文献
引用本文

郑新平.温肾健脾汤联合美沙拉嗪治疗溃疡性结肠炎临床研究[J].新中医,2022,54(8):93-96

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2022-04-24
  • 出版日期:
文章二维码